![](/img/cover-not-exists.png)
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Robert, Caroline, Dummer, Reinhard, Gutzmer, Ralf, Lorigan, Paul, Kim, Kevin B, Nyakas, Marta, Arance, Ana, Liszkay, Gabriella, Schadendorf, Dirk, Cantarini, Mireille, Spencer, Stuart, Middleton, MarkVolume:
14
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(13)70237-7
Date:
July, 2013
File:
PDF, 227 KB
english, 2013